Compare McKesson Corporation (MCK) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Marsh & McLennan Companies, Inc. — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: McKesson Corporation is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| MCK | MRSH | |
|---|---|---|
Market Cap | $108.46B | $84.31B |
Volume | 712,607 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $995.69 | $207.02 |
52-Week Low | $725.17 | $157.32 |
Typical Hold Time | 74 Days | 109 Days |
Enterprise Value | $115.00B | $104.99B |
Dividend Yield | 0.4% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Marsh (MRSH) trades at $176.67, up 1.73% today, near its consensus price target of $202.71. The stock shows a bullish technical trend with support at $174 and resistance at $178. Recent earnings beats and the acquisition of Accel Holdings highlight strong operational momentum. Revenue grew to $27.0B in 2025, with a net income margin of 14.24% and a P/E ratio of 21.57, indicating solid profitability amid moderate valuation.
The outlook remains positive with consistent earnings outperformance and strategic acquisitions driving growth. Risks include elevated debt levels and potential margin pressure. Analysts are mostly neutral (65% Hold), but the stock offers upside to the price target. Investors should weigh strong cash flow generation against macroeconomic sensitivities in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
